Indeed, the overexpression of UBE2C was previously reported in hepatocellular carcinoma, thyroid, colon, breast, and lung cancer [8,9,10,11,12,13] and our data confirmed this upregulation (Figure 1). Here, UBE2C is linked to hepatocellular carcinoma.